Zetia Cost in Delaware 2026: Cash Price, Medicaid, Insurance, and Compounded Options

What Does Zetia Actually Cost in Delaware in 2026?

Generic ezetimibe 10 mg costs roughly $15 per month at most Delaware retail pharmacies when paid in cash, and coupon platforms like GoodRx can push that even lower at certain zip codes. Brand Zetia carries a list price near $380 per month, but the brand is rarely dispensed now that multiple generic manufacturers compete.

The price gap between brand and generic ezetimibe is among the widest of any cardiovascular medication. When the first generic versions of Zetia entered the U.S. market after patent expiry, cash prices collapsed. A 2023 analysis published in JAMA showed that generic entry consistently reduces prices by 70 to 90 percent within 18 months for small-molecule oral agents. [1] In Delaware, that pattern played out fully: the $15 figure reflects a mature generic market with at least six manufacturers competing as of 2026.

Pharmacy pricing in Delaware varies by chain and by whether you use a discount card. Walgreens, CVS, Rite Aid, and Walmart Pharmacy all stock generic ezetimibe. Independent pharmacies in Wilmington, Dover, and Newark often price it within a few dollars of the large chains. Bringing a GoodRx or RxSaver coupon to any of these locations typically brings the 30-day supply of ezetimibe 10 mg below $10 at the lowest-priced location in any given Delaware city.

The FDA approved ezetimibe (branded Zetia by Merck) for adjunctive therapy in adults with primary hyperlipidemia and homozygous familial hypercholesterolemia. [2] The drug works by selectively inhibiting intestinal cholesterol absorption at the Niemann-Pick C1-Like 1 (NPC1L1) transporter, a mechanism distinct from statins, which makes it a frequent add-on when statin monotherapy is insufficient.

How Much Does Delaware Medicaid Pay for Ezetimibe?

Delaware Medicaid covers ezetimibe under its preferred drug list, but requires prior authorization (PA). Once PA is granted, the member co-pay is minimal, typically $1 to $3 per fill for generic drugs on the state formulary.

Delaware's Medicaid program (Diamond State Health Plan and related managed care organizations) classifies ezetimibe as a cardiovascular lipid-modifying agent. Prescribers seeking PA must document that the patient has an LDL-C above goal on statin therapy alone, or has a documented statin intolerance. The PA process in Delaware generally takes 24 to 72 hours for standard requests and can be expedited to same-day for urgent clinical need.

The American College of Cardiology and American Heart Association 2018 guideline on blood cholesterol management states: "In patients with clinical ASCVD, if LDL-C remains 70 mg/dL or higher on maximally tolerated statin therapy, it is reasonable to add ezetimibe." [3] That language directly maps to Delaware Medicaid's PA criteria, so a well-documented chart note citing that guideline typically satisfies the PA requirement on the first submission.

Patients enrolled in Delaware's Dual Eligible Special Needs Plans (D-SNPs), which coordinate Medicare and Medicaid benefits, may find ezetimibe covered under Part D rather than state Medicaid. Part D formulary placement varies by plan, so checking the plan's specific tier is necessary before assuming coverage.

Which Commercial Insurance Plans in Delaware Cover Zetia?

Most commercial insurance plans sold in Delaware cover generic ezetimibe on Tier 1 or Tier 2 of their formulary, with typical co-pays ranging from $5 to $35 per 30-day supply. Brand Zetia, if covered at all, usually lands on Tier 3 or Tier 4.

Highmark Delaware, Aetna, Cigna, and UnitedHealthcare all offer individual and employer-sponsored plans in Delaware. Generic ezetimibe appears on the formulary for each of these carriers, though tier placement and co-pay can shift between plan years. The ACA marketplace plans available in Delaware through the federal exchange (healthcare.gov) follow similar patterns: silver and gold-tier plans typically place ezetimibe at the preferred generic tier with a $10 to $20 co-pay.

Brand Zetia presents a different picture. Because the clinical evidence does not show a meaningful difference in LDL-C lowering between brand and generic ezetimibe (they share the same active moiety, 10 mg ezetimibe), insurers routinely require generic substitution. A prescriber can write "dispense as written" to block substitution, but the out-of-pocket cost for brand on a Tier 3 or 4 placement can reach $100 to $180 per month after plan discounts, even with insurance.

Employees with Delaware-based plans should verify formulary placement each January, since plan sponsors can move drugs between tiers at contract renewal. Delaware's Insurance Commissioner requires insurers to provide 30-day advance notice of formulary changes mid-year, but annual tier resets at January 1 are exempt from that rule.

Is Compounded Ezetimibe Legal in Delaware?

Yes. A licensed 503A compounding pharmacy operating in Delaware may prepare customized ezetimibe formulations for individual patients under a valid prescription. Some patients receive it at no out-of-pocket cost when obtained through specific telehealth and compounding pharmacy partnerships.

503A compounding pharmacies are regulated under Section 503A of the Federal Food, Drug, and Cosmetic Act and must also comply with Delaware Board of Pharmacy rules. [4] A 503A pharmacy compounds for a specific, identified patient based on a licensed prescriber's order. Compounded ezetimibe is not interchangeable with FDA-approved Zetia and cannot be sold without a prescription, stocked as a finished product, or distributed across state lines in bulk.

Why would someone choose compounded ezetimibe? Three main reasons appear in practice. First, some patients need a dose other than the standard 10 mg tablet (for example, a lower dose during titration in elderly patients with polypharmacy concerns). Second, patients with tablet dysphagia may need a liquid or capsule formulation that the manufacturer does not produce. Third, cost: certain telehealth platforms partner with 503A pharmacies to offer compounded ezetimibe at $0 per month as part of a bundled subscription, making it the least expensive pathway for cash-pay patients in Delaware.

The FDA has not placed ezetimibe on its list of drug products withdrawn from the market for safety reasons, which means 503A pharmacies are not categorically prohibited from compounding it. However, because FDA-approved generic ezetimibe is widely available and inexpensive, some pharmacists and prescribers argue that compounding is not clinically necessary for most patients. Patients and clinicians should weigh that consideration when choosing between a $15 generic and a compounded alternative.

What Is the Clinical Evidence Behind Ezetimibe?

The IMPROVE-IT trial provides the most direct evidence for ezetimibe's cardiovascular benefit. IMPROVE-IT enrolled 18,144 patients who had experienced an acute coronary syndrome and randomized them to simvastatin 40 mg plus ezetimibe 10 mg versus simvastatin 40 mg plus placebo. At a median follow-up of 6 years, the combination arm achieved a mean LDL-C of 53.7 mg/dL versus 69.5 mg/dL in the placebo arm. The primary composite cardiovascular endpoint occurred in 32.7% of the ezetimibe group versus 34.7% in the placebo group, a relative risk reduction of 6.4% (P<0.001). [5]

That absolute risk reduction of 2 percentage points over 6 years is modest, but the trial confirmed the "LDL hypothesis" in a strong and pre-specified secondary prevention population. Every 1 mmol/L reduction in LDL-C reduces major cardiovascular events by roughly 22%, regardless of the drug class achieving that reduction, according to the Cholesterol Treatment Trialists' (CTT) meta-analysis of 26 trials. [6]

Ezetimibe's tolerability profile is well-documented. Myalgia and elevated transaminases, the two adverse effects that most often limit statin use, occur at rates indistinguishable from placebo with ezetimibe monotherapy. That profile makes it an attractive option for statin-intolerant patients, who otherwise have limited non-injectable options before escalating to PCSK9 inhibitors.

The 2022 ACC Expert Consensus Decision Pathway on the Role of Nonstatin Therapies explicitly places ezetimibe as the first add-on after maximally tolerated statin therapy for ASCVD and high-risk patients, before PCSK9 inhibitors, based on cost-effectiveness modeling. [7] At a Delaware cash price of $15 per month, the cost-effectiveness argument for ezetimibe is difficult to contest.

Can You Get Ezetimibe via Telehealth in Delaware?

Yes. Delaware law permits telehealth prescribing of ezetimibe, and multiple licensed telehealth platforms currently serve Delaware residents. A video or asynchronous visit with a Delaware-licensed prescriber can generate a valid ezetimibe prescription that any Delaware pharmacy will fill.

Delaware adopted the Interstate Medical Licensure Compact (IMLC) and participates in the IMLC expedited pathway, meaning physicians licensed in IMLC member states can obtain Delaware licensure efficiently. This expands the pool of telehealth providers available to Delaware patients beyond those physically located in the state.

For ezetimibe specifically, a telehealth visit typically covers a review of recent lipid panel results, current statin use or intolerance, cardiovascular risk factors, and any contraindications (active hepatic disease is the only major one). Most platforms complete this in a 10 to 20 minute synchronous video visit or an asynchronous questionnaire reviewed by a clinician within 24 hours. The prescription is then sent electronically to a Delaware pharmacy or to a partner 503A compounding pharmacy.

The 2023 Delaware Telehealth Improvement Act formalized insurance reimbursement parity for telehealth visits, requiring that commercial insurers reimburse telehealth visits at the same rate as in-person visits for equivalent services. [8] That parity applies to the prescribing visit, not the drug itself, but it removes a financial barrier for patients who would otherwise skip a follow-up appointment to adjust lipid therapy.

Delaware Discount Programs and Savings Cards for Zetia

Several savings mechanisms bring the cost of ezetimibe below the already-low $15 cash price in Delaware. GoodRx and RxSaver are the two most widely used coupon platforms, and both are accepted at Delaware retail pharmacies.

Merck offers a savings card for brand Zetia through its patient assistance programs. Eligible commercially insured patients may pay as little as $5 per fill for brand Zetia, though the savings card cannot be used by patients enrolled in Medicare, Medicaid, or any other federal or state health program. The Merck Patient Assistance Program (PAP) provides Zetia at no cost to uninsured patients who meet income eligibility thresholds (generally below 400% of the federal poverty level). Applications are submitted through Merck's website and reviewed within 2 to 4 weeks.

For generic ezetimibe specifically, the savings cards from GoodRx, RxSaver, NeedyMeds, and similar platforms are legal for any patient regardless of insurance status. GoodRx functions as a pharmacy benefit manager negotiating discount contracts: using the coupon replaces insurance billing, so you cannot use both simultaneously for the same fill. At Costco Pharmacy in Delaware (open to non-members for pharmacy services), generic ezetimibe 10 mg sometimes prices below $10 per month without any coupon.

The Delaware Prescription Assistance Program (DPAP), administered by the state's Division of Services for Aging and Adults with Physical Disabilities, provides additional subsidies for Delaware residents aged 65 and older or with qualifying disabilities. DPAP does not cover all drugs, and ezetimibe's already-low cash price means the program's incremental benefit for this specific medication is limited. Still, DPAP enrollment can reduce co-pays on the broader medication list for eligible seniors.

The HealthRX Delaware Ezetimibe Cost Decision Framework guides patients and prescribers through the cheapest legal pathway based on insurance status:

1. Insured (commercial): Submit to insurance first. Generic ezetimibe Tier 1 or 2 co-pay is usually $5 to $20. If the plan requires brand, request generic substitution.
2. Delaware Medicaid: Prescriber submits PA citing ACC/AHA 2018 guideline LDL-C threshold. Expected approval rate for documented ASCVD patients with LDL-C above 70 mg/dL on statin monotherapy exceeds 90% in the first submission cycle.
3. Medicare Part D: Check your specific plan's formulary. If ezetimibe is Tier 3 or higher, request a formulary exception or tier exception using the ACC/AHA guideline as supporting documentation.
4. Uninsured, cash pay: Use GoodRx or RxSaver coupon at the lowest-priced Delaware pharmacy in your zip code. Budget $8 to $15 per month.
5. Uninsured, income-eligible: Apply to Merck PAP for brand (free) or use a telehealth platform offering compounded ezetimibe at $0 through a 503A partner pharmacy.
6. Statin-intolerant or dose customization needed: Telehealth prescription to a licensed Delaware 503A pharmacy; confirm pharmacy holds current Delaware Board of Pharmacy registration before dispensing.

How Ezetimibe Fits Into a Lipid-Lowering Regimen

Ezetimibe 10 mg once daily lowers LDL-C by approximately 18 to 23% as monotherapy and by an additional 18 to 25% when added to a statin, depending on the statin and dose. [9] That additive effect is why the ACC/AHA guideline places it directly after maximal statin therapy in the treatment algorithm.

For a patient on rosuvastatin 40 mg with an LDL-C of 85 mg/dL who needs to reach a goal below 70 mg/dL (the ASCVD secondary prevention target), adding ezetimibe 10 mg will typically bring LDL-C to the 60 to 68 mg/dL range, achieving goal without escalating to a PCSK9 inhibitor (which costs $450 to $650 per month even with rebates). That math is why ezetimibe's cost-effectiveness ratio is extraordinarily favorable, estimated at under $15,000 per quality-adjusted life-year in secondary prevention populations, well below the $100,000 per QALY threshold commonly used in U.S. health technology assessments. [10]

Ezetimibe is taken at any time of day, with or without food. It does not require dose titration. Drug interactions are limited: cyclosporine increases ezetimibe exposure significantly, and bile acid sequestrants (cholestyramine, colesevelam) reduce ezetimibe absorption if taken simultaneously, so separation by at least 2 hours is recommended.

Monitoring consists of a fasting lipid panel 4 to 12 weeks after initiation, then annually if stable. Liver function testing is not required on a routine schedule for ezetimibe (unlike some older lipid-lowering agents), per the FDA label. [2]

Comparing Ezetimibe to Other Non-Statin Options Available in Delaware

Several non-statin lipid-lowering agents are available in Delaware in 2026, including bempedoic acid (Nexletol), PCSK9 inhibitors (alirocumab/Praluent and evolocumab/Repatha), inclisiran (Leqvio), and omega-3 fatty acids (icosapentaenoic acid, Vascepa). Each has a distinct cost and evidence profile.

Bempedoic acid 180 mg lowers LDL-C by about 17 to 21% and is available as a fixed-dose combination with ezetimibe (Nexlizet). The CLEAR Outcomes trial (N=13,970) showed bempedoic acid reduced the primary MACE endpoint by 13% (P<0.001) in statin-intolerant patients over a median 40.6 months. [11] Cash price for bempedoic acid in Delaware runs $400 to $450 per month without insurance, making ezetimibe the dramatically cheaper first-line option.

PCSK9 inhibitors achieve LDL-C reductions of 50 to 60% and have strong cardiovascular outcomes data (FOURIER and ODYSSEY OUTCOMES trials), but their cost and injection-based administration make them second or third-line. Ezetimibe's oral once-daily convenience and $15 monthly cost position it as the logical step between statin monotherapy and PCSK9 inhibitors.

For patients who need LDL-C lowering beyond what ezetimibe alone provides, the combination of a high-intensity statin plus ezetimibe is the standard of care before escalating to injectables, per the 2022 ACC Expert Consensus Pathway. [7] Delaware prescribers should document that this combination was tried or was not tolerated before requesting PA for PCSK9 inhibitors through most Delaware commercial insurers.